NASDAQ:MAZE Maze Therapeutics 3/31/2025 Earnings Report $16.01 +0.27 (+1.72%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Maze Therapeutics EPS ResultsActual EPS-$18.32Consensus EPS -$7.60Beat/MissMissed by -$10.72One Year Ago EPSN/AMaze Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMaze Therapeutics Announcement DetailsQuarterDate3/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Maze Therapeutics Earnings HeadlinesBrokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $23.50July 13 at 3:33 AM | americanbankingnews.comQ2 Earnings Estimate for Maze Therapeutics Issued By WedbushJuly 11, 2025 | americanbankingnews.comPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.July 15 at 2:00 AM | Paradigm Press (Ad)Maze Therapeutics to Participate in Two Upcoming Investor ConferencesJuly 10, 2025 | globenewswire.comMAZE Stock Price Quote | MorningstarJuly 9, 2025 | morningstar.comMWedbush Initiates Coverage of Maze Therapeutics (MAZE) with Outperform RecommendationJuly 9, 2025 | msn.comSee More Maze Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email. Email Address About Maze TherapeuticsMaze Therapeutics (NASDAQ:MAZE) (NASDAQ: MAZE) is a clinical-stage biotechnology company dedicated to unlocking the power of human genetics to develop precision therapies for cardiometabolic and related diseases. Since its founding, the firm has combined large-scale genetic analysis with functional genomics and advanced computational biology to identify and validate novel drug targets that arise from naturally occurring human variants. The company’s proprietary discovery platform integrates extensive population-scale genetic datasets, machine learning algorithms and laboratory assays to accelerate the translation of genetic insights into therapeutic candidates. This approach enables Maze to prioritize targets with strong human validation and to optimize small-molecule or biologic modalities with a higher probability of clinical success. Maze’s development pipeline comprises multiple preclinical and IND-enabling programs addressing conditions such as dyslipidemia, nonalcoholic steatohepatitis and other metabolic disorders. The company collaborates with leading academic institutions, research consortia and industry partners to expand its target portfolio and to advance its most promising programs into early-stage clinical trials. Headquartered in South San Francisco with research operations in California and Europe, Maze Therapeutics is guided by a management team of seasoned industry veterans. Its leadership brings deep expertise in genetics-based drug discovery, clinical development and regulatory strategy, positioning the company to deliver transformative therapies for patients with unmet medical needs.Written by Jeffrey Neal JohnsonView Maze Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025)Johnson & Johnson (7/16/2025)Kinder Morgan (7/16/2025)Morgan Stanley (7/16/2025)Progressive (7/16/2025)Prologis (7/16/2025)The PNC Financial Services Group (7/16/2025)Cintas (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
